Antisense inhibition of E2A-Pbx1 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrett P. Monia, Edward Wancewicz
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for inhibiting E2A-Pbx1 mediated transformation. The compositions comprise antisense compounds targeted to nucleic acids encoding E2A-Pbx1. Methods of using these antisense compounds for inhibition of E2A-Pbx1 expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of E2A-Pbx1 are provided.
Claims25
An antisense compound 8 to 30 nucleobases in length targeted to nucleobases 1 through 20 of a 5′ untranslated region, nucleobases 23 through 42 of a start codon region, nucleobases 176-195, or nucleobases 699 through 718 of a nucleic acid molecule encoding E2 A-Pbx1 of SEQ ID NO:
- 1, or nucleobases 376 through 395, nucleobases 1105 through 1124, or nucleobases 1594 through 1613 of a coding region, or nucleobases 1725 through 1744, nucleobases 1816 through 1835, or nucleobases 1955 through 1974 of a 3′-untranslated region of a nucleic acid encoding E2A-Pbx1 of SEQ ID NO:
- 2, wherein said antisense compound specifically hybridizes with one of said regions and inhibits the expression of E2A-Pbx1.
An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 3, 4, 5, 7, 9, 10, 13, 15, 17, 18 or 20 which inhibits the expression of E2A-Pbx1.
Dependencies are inferred from the claim text.